# UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone

> **NCT03139747** · PHASE2 · SUSPENDED · sponsor: **Thomas Jefferson University** · enrollment: 5 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT03139747
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2017-04-03
- **Primary completion:** 2022-05-30
- **Final completion:** 2022-05-30
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** lack of accrual reevaluating feasibility
- **Last updated:** 2021-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03139747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03139747, "UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03139747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*